• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Sarepta Therapeutics (NQ: SRPT )

    117.75 +0.63 (+0.54%)
    Streaming Delayed Price Updated: 11:25 AM EDT, Apr 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 106,165
    Open 117.66
    Bid (Size) 117.67 (2)
    Ask (Size) 117.83 (1)
    Prev. Close 117.12
    Today's Range 117.21 - 118.72
    52wk Range 55.25 - 159.89
    Shares Outstanding 93,148,652
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst
    Sarepta stock has taken a beating this year, and it might not be over with the first-quarter report looming. 
    Via Investor's Business Daily

    Performance

    YTD
    +22.39%
    +22.39%
    1 Month
    -7.96%
    -7.96%
    3 Month
    -2.79%
    -2.79%
    6 Month
    +3.82%
    +3.82%
    1 Year
    -7.05%
    -7.05%

    More News

    Read More
    2 Biotech Stocks to Buy Hand Over Fist in April
    Via The Motley Fool
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics: Q4 Earnings Insights
    Via Benzinga
    A Preview Of Sarepta Therapeutics's Earnings
    Via Benzinga
    How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback
    Via Investor's Business Daily
    Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
    Via The Motley Fool
    This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
    Via Benzinga
    Got $1,000? Buy These Hot Growth Stocks Before They Take Off.
    Via The Motley Fool
    Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
    Via The Motley Fool
    Sarepta Therapeutics to Present at Upcoming Investor Conferences
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Is It Too Late to Buy Sarepta Therapeutics Stock?
    Via The Motley Fool
    Earnings Scheduled For February 28, 2024
    Via Benzinga
    Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices
    Via Benzinga
    Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    FDA Fast-Tracks Review Of Sarepta's Groundbreaking Muscular Dystrophy Treatment With $1B Market In Sight
    Via Benzinga
    Exposures Product Safety
    Why DoorDash Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.